An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

October 26, 2018 updated by: Vitae Pharmaceuticals Inc., an Allergan affiliate

A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients

This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose panels.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a prospective, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics effects of VTP-43742 in healthy volunteers conducted at a single, study center and in patients with moderate to severe chronic plaque-type psoriasis at approximately 8 study centers in the United States. A total of 108 participants will be enrolled in the study (48 healthy subjects and 60 psoriatic patients).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
74

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arkansas
      • Rogers, Arkansas, United States, 72758
        • Patient Site 5
    • Florida
      • Miami, Florida, United States, 33144
        • Patient Site 1
      • Tampa, Florida, United States, 33609
        • Patient Site 8
      • Tampa, Florida, United States, 33624
        • Patient 12
    • Indiana
      • Carmel, Indiana, United States, 46032
        • Patient Site 13
      • Plainfield, Indiana, United States, 46168
        • Patient Site 4
    • New Jersey
      • Fair Lawn, New Jersey, United States, 07410
        • Healthy Volunteer Site 1
    • New York
      • New York, New York, United States, 10012
        • Patient Site 2
    • North Carolina
      • High Point, North Carolina, United States, 27265
        • Patient Site 9
    • Texas
      • College Station, Texas, United States, 77845
        • Patient Site 6
      • Dallas, Texas, United States, 75231
        • Patient Site 3
      • Houston, Texas, United States, 77004
        • Patient Site 10
      • Houston, Texas, United States, 77065
        • Patient Site 11
      • Webster, Texas, United States, 77598
        • Patient Site 7

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Healthy Volunteer Inclusion Criteria:

  • Healthy males or females, 18 to 45 years of age, inclusive.
  • Body weight of at least 55 kg and body mass index of 18-32 kg/m2, inclusive.
  • Medically healthy with clinically insignificant screening results.
  • Women of child-bearing potential (WOCBP) may be enrolled if they agree to use two of the reliable forms of contraception
  • Men with partners who are WOCBP must agree that they and/or their partner will use two of the reliable forms of contraception
  • WOCBP must have a negative serum βhCG pregnancy test at the Check-in visit.
  • Voluntarily consent to participate in the trial

Psoriasis Patient Inclusion Criteria:

  • Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months before study with at least moderate severity, which is defined as PASI≥10, PGA≥3, and % BSA≥8
  • Otherwise medically healthy and with otherwise clinically insignificant screening laboratory test results
  • Males or females, 18 to 75 years of age, inclusive
  • Body weight of at least 55 kg and body mass index of 18-35 kg/m2, inclusive.
  • WOCBP may be enrolled if they agree to use two of the reliable forms of contraception
  • Men with partners who are WOCBP must agree that they and/or their partner will use two of the reliable forms of contraception
  • WOCBP must have a negative serum β hCG pregnancy test at the Screening and Baseline visit
  • Voluntarily consent to participate in the trial

Healthy Volunteer Exclusion Criteria:

  • Unwilling or unable to provide written informed consent
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, coagulation, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • Evidence of organ dysfunction or any clinically significant deviation from normal in vital signs, physical examination, clinical laboratory determinations or ECG
  • Any major surgery within 3 months of Screening
  • Positive urine drug/alcohol testing at Screening or Baseline visit
  • Use of tobacco and/or nicotine-containing products within 3 months prior to the start of dosing of the trial
  • Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at Screening
  • History or presence of alcoholism or drug abuse as defined in DSM V, Diagnostic Criteria for Drug and Alcohol Abuse
  • History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes
  • Any previous gastrointestinal surgery or recent (within 3 months) history of gastrointestinal disease that could impact the absorption of the study drug
  • Blood donation or significant blood loss within 8 weeks prior to Day 1of the trial
  • Plasma donation within 7 days prior to Day 1 of the trial
  • Blood transfusion within 4 weeks of Screening
  • Positive serum pregnancy test (WOCBP) at the Screening or Baseline visit
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease) must not be enrolled into this study
  • Any other medical, psychiatric, and /or social reason as determined by the Investigator

Psoriatic Patient Exclusion Criteria:

  • Unwilling or unable to provide written informed consent
  • Efficacy failure on two or more biological agents for the treatment of psoriasis when the failures occurred within one year of the initiation of the therapy of the first biological agent
  • Current treatment or history of treatment for psoriasis with biologicals within 6 months of study Day 1
  • Current treatment or history of treatment for psoriasis with non-biological systemic medications within 4 weeks of Day 1 and treatment with topical agents within 2 weeks of Day 1
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, coagulation, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • Evidence of organ dysfunction or any clinically significant deviation from normal in vital signs, physical examination, clinical laboratory determinations or ECG
  • Any major surgery within 3 months of Screening
  • Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at Screening
  • History or presence of alcoholism or drug abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse
  • History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes
  • Any previous gastrointestinal surgery or recent (within 3 months) history of gastrointestinal disease that could impact the absorption of the study drug
  • Blood donation or significant blood loss within 8 weeks prior to Day 1 of the trial
  • Plasma donation within 7 days prior to Day 1 of the trial
  • Blood transfusion within 4 weeks of Screening
  • Positive serum pregnancy test (WOCBP) at the Screening or positive urine pregnancy test with confirmatory serum pregnancy test on Day 1
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease) must not be enrolled into this study.
  • Any other medical, psychiatric, and /or social reason as determined by the Investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo 1
healthy volunteers
Drug: Placebo 1
Placebo 1 matching VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 1
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 2
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 3
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 4
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 5
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 6
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 7
healthy volunteers
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Placebo Comparator: Placebo 2
psoriatic patients
Drug: Placebo 2
Placebo 2 matching VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 8
psoriatic patients
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 9
psoriatic patients
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 10
psoriatic patients
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily
Experimental: VTP-43742 Dose 11
psoriatic patients
Drug: VTP-43742
VTP-43742 administered as an oral capsule once daily

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
safety data, including AEs, laboratory evaluations, ECG results, and vital signs assessments, will be listed by subject and summarized by dose and time point
Time Frame: 10 days
10 days
safety data, including AEs, laboratory evaluations, ECG results, and vital signs assessments, will be listed by subject and summarized by dose and time point
Time Frame: 28 days
28 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Maximum plasma concentration (Cmax) will be summarized using descriptive statistics by visit and dose level
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28
Time to maximum plasma concentrations (tmax) will be summarized using descriptive statistics by visit and dose level
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28
The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration (AUCt) will be summarized using descriptive statistics by visit and dose level
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28
The area under the plasma concentration versus time curve, from time 0 to infinity (by extrapolation) (AUC∞) will be summarized using descriptive statistics by visit and dose level
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28
Half life (t½) will be summarized using descriptive statistics by visit and dose level
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28
Percent change from baseline in total PASI will be summarized using descriptive statistics by visit and dose level
Time Frame: 28 days
28 days

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Time Frame
changes from baseline and/or placebo for IL-17 plasma levels
Time Frame: Day 1, 10 and 28
Day 1, 10 and 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Vitae Pharmaceuticals Inc., an Allergan affiliate

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Richard Gregg, MD, Vitae Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 15, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 18, 2015

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 21, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 30, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 26, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • VTP-43742-002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on Placebo 1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings